Compare LCTX & AMWL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | LCTX | AMWL |
|---|---|---|
| Founded | 1990 | 2006 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Retail: Computer Software & Peripheral Equipment |
| Sector | Health Care | Technology |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 407.7M | 92.0M |
| IPO Year | 1996 | 2020 |
| Metric | LCTX | AMWL |
|---|---|---|
| Price | $1.46 | $5.66 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 2 | 7 |
| Target Price | $6.00 | ★ $7.42 |
| AVG Volume (30 Days) | ★ 1.1M | 65.1K |
| Earning Date | 03-05-2026 | 04-30-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 57.06 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $14,556,000.00 | N/A |
| Revenue This Year | $55.75 | N/A |
| Revenue Next Year | $2.96 | $4.24 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 53.24 | N/A |
| 52 Week Low | $0.37 | $3.71 |
| 52 Week High | $2.09 | $9.15 |
| Indicator | LCTX | AMWL |
|---|---|---|
| Relative Strength Index (RSI) | 32.08 | 55.96 |
| Support Level | $0.94 | $4.48 |
| Resistance Level | $1.84 | $5.81 |
| Average True Range (ATR) | 0.11 | 0.35 |
| MACD | -0.04 | -0.02 |
| Stochastic Oscillator | 1.85 | 59.09 |
Lineage Cell Therapeutics Inc is a clinical-stage biotechnology company focused on the development and commercialization of novel therapies for the treatment of degenerative diseases. The company's pipeline is based on two platform technologies including cell replacement and cell/drug delivery. Lineage Cell's product candidate is OpRegen, a retinal pigment epithelium transplant therapy for the treatment of dry age-related macular degeneration, OPC1, an oligodendrocyte progenitor cell therapy for acute spinal cord injuries, and VAC2, allogeneic cancer immunotherapy of antigen-presenting dendritic cells for non-small cell lung cancer, ANP1, an allogeneic auditory neuron progenitor cells transplant for hearing loss, and PNC1, an allogeneic photoreceptor cell transplant for vision loss.
American Well Corp is an enterprise platform and software company digitally enabling hybrid care by offering payers and health systems a technology-enabled care platform. The Amwell Platform, its cloud-based enablement platform, digitally enables a scalable healthcare experience across all care settings by enabling critical services like virtual primary care, urgent care, clinical partner programs, scheduling visits, etc. Additionally, the healthcare providers can use the platform to access familiar workflows for taking notes, prescribing, referencing clinical treatment guidelines, and other related activities. The firm also offers various paid services, including licensed clinical staffing, implementation support, workflow design, etc, to help clients execute their hybrid care strategies.